Turn Therapeutics (TTRX) Open Investor Session materials presentation summary

Key milestones and development timeline

• Achieved multiple FDA clearances for GX-03/Hexagen in wound and dermatitis management since 2016, with over 200,000 patients treated and zero adverse events reported.

• Entered a license and development partnership with MIMEDX in December 2022, with exclusive licensing for Flex AM and a $70M milestone and royalty structure.

• Phase 2 trial for moderate-severe eczema began in July 2025, with Phase 3 for both eczema and onychomycosis expected to initiate in 2026.

• GX-03 demonstrated efficacy in investigator-initiated trials for onychomycosis, basal cell carcinoma, and ocular diseases.

• Confirmation of cytokine modulation (IL31/IL36/IL4) for GX-03 in moderate-severe eczema in 2024.

Product portfolio and technology

• PermaFusion is a patented, API-agnostic drug delivery platform enabling stable, emulsifier-free dispersion of active ingredients in oil-based carriers.

• GX-03/Hexagen is FDA-cleared for advanced wound and dermatitis management, with a strong safety profile and documented efficacy in both skin and nail conditions.

• Product pipeline includes moderate-severe eczema (Phase 2), onychomycosis (Phase 3 planned), and a thermostable intranasal vaccine platform.

• XEAL, an antimicrobial oil emulsion dressing powered by Hexagen, is FDA-cleared and in active negotiations for exclusive licensing.

Market opportunities and clinical data

• Eczema and onychomycosis represent high-value markets, with 6.6 million annual US eczema patients and a $6B global market, and onychomycosis with a $3.8B global market.

• GX-03/Hexagen demonstrated 70-85% efficacy in preliminary physician-led trials for onychomycosis, outperforming current topical antifungals.

• Cytokine studies show strong inhibition of IL-36a, IL-36y, and IL-31, key drivers of eczema inflammation, with significant clinical improvement in animal and human models.

• Intranasal vaccine platform demonstrated increased thermostability, maintaining live virus at room temperature for over 14 days.